Soligenix, INC

Soligenix, Inc. announced that its stockholders approved an increase in authorized common stock and a reverse stock split at the 2026 annual meeting.

Soligenix, Inc. has filed a prospectus supplement to increase its existing 'at-the-market' equity offering program by an additional $2.5 million.

Soligenix, Inc. has terminated its HyBryte development program following a failed clinical trial and received a Nasdaq deficiency notice regarding its share price.

Soligenix, Inc. has filed a prospectus supplement to increase its existing at-the-market equity offering program by an additional $2.96 million.

Soligenix, Inc. announced its Phase 3 FLASH2 trial for HyBryte in cutaneous T-cell lymphoma was recommended to halt for futility, prompting a strategic review.

Soligenix, Inc. has entered into an At Market Issuance Sales Agreement with Rodman & Renshaw, LLC to potentially sell up to $3.45 million of common stock.

Soligenix, Inc. reported increased net losses in Q3 2025, driven by higher R&D expenses, but regained Nasdaq compliance through a recent public offering.

Soligenix, Inc. reported a significant increase in net loss for Q2 2025, raising substantial doubt about its ability to continue as a going concern despite ongoing clinical trial progress.

Soligenix reports a net loss for Q1 2025 and expresses concerns about its ability to continue as a going concern without securing additional funding.

Soligenix, Inc. released its third quarter 2024 financial results, highlighting advancements in its clinical programs and ongoing efforts to secure funding.

Soligenix reported a net loss of $3.56 million for the first half of 2024, while advancing its pipeline programs and securing additional funding.

Soligenix reported a net loss for the first quarter of 2024 and expressed substantial doubt about its ability to continue as a going concern.

Soligenix, a late-stage biopharmaceutical company, details its 2024 financial results and provides updates on its key development programs, including HyBryte for cutaneous T-cell lymphoma.

Soligenix's 10-K filing details its authorized capital stock, ongoing clinical trials, and financial position, highlighting both opportunities and challenges.

Jerome B Zeldis, a Director of Soligenix, Inc., received 78,947 shares of common stock on September 17, 2026.

Robert J. Rubin, a Director of Soligenix, Inc., received 78,947 shares of common stock on September 17, 2026.

Diane L. Parks, a Director of Soligenix, Inc., received 78,947 shares of common stock on September 17, 2026.

Anthony Gregg Lapointe, a Director of Soligenix, Inc., received 78,947 shares of common stock on September 17, 2026.

Soligenix, Inc. CMO Richard Straube was granted 10,000 stock options with an exercise price of $1.63, vesting over time.

Soligenix Chief Scientific Officer Oreola Donini acquired 100,000 stock options with an exercise price of $1.63, vesting over time.

Soligenix, Inc. announces its 2025 Annual Meeting of Stockholders to be held on June 20, 2025, outlining proposals including the election of directors, approval of the 2025 Equity Incentive Plan, and ratification of the independent auditor.

Soligenix has released its proxy statement, urging stockholders to vote on key proposals including the election of directors, approval of the 2025 Equity Incentive Plan, and executive compensation.

Soligenix, Inc. reminds shareholders to participate in the Annual Meeting of Shareholders by voting through www.proxyvote.com or by phone before the deadline.

Soligenix reminds shareholders to vote before the upcoming Annual Meeting of Shareholders.

Soligenix, Inc. reminds shareholders to participate in the Annual Meeting of Shareholders by voting via www.proxyvote.com or phone before the deadline.

Soligenix encourages shareholders to participate in the Annual Meeting of Shareholders by voting their shares.

Soligenix, a late-stage biopharmaceutical company, is offering up to $8.0 million in common stock and warrants to address its liquidity concerns and regain compliance with Nasdaq's minimum stockholders' equity requirement.

Soligenix is registering up to 1,054,688 shares of common stock for resale by selling stockholders following the exercise of warrants.

Soligenix, Inc. plans to raise up to $10 million through a public offering of common stock and warrants to fund research, development, and general corporate purposes.

Soligenix, a late-stage biopharmaceutical company, plans to raise up to $10 million through a public offering of common stock and warrants to fund research, development, and commercialization activities.

Soligenix, a late-stage biopharmaceutical company, announces a proposed public offering to raise up to $10 million through the sale of common stock and warrants.

MJL Manager LLC and Michael Liu have filed a Schedule 13G disclosing a combined beneficial ownership of 5.7% in Soligenix, Inc. common stock.

Armistice Capital, LLC and Steven Boyd have reported a 6.72% beneficial ownership stake in Soligenix, Inc., totaling 708,000 shares of common stock.

Intracoastal Capital, along with Mitchell P. Kopin and Daniel B. Asher, reported a 4.99% beneficial ownership stake in Soligenix, Inc. as of October 1, 2025.